$28.11
2.63% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US90400D1081
Symbol
RARE

Ultragenyx Pharmaceutical, Inc. Stock price

$28.11
-1.12 3.83% 1M
-15.32 35.28% 6M
-13.96 33.18% YTD
-22.79 44.77% 1Y
-23.46 45.49% 3Y
-55.70 66.46% 5Y
-86.81 75.54% 10Y
-14.14 33.47% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.72 2.63%
ISIN
US90400D1081
Symbol
RARE
Industry

Key metrics

Basic
Market capitalization
$2.6b
Enterprise Value
$2.2b
Net debt
positive
Cash
$487.6m
Shares outstanding
96.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.3 | 4.0
EV/Sales
3.5 | 3.2
EV/FCF
negative
P/B
17.5
Financial Health
Equity Ratio
17.0%
Return on Equity
-223.0%
ROCE
-49.9%
ROIC
-70.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$610.2m | $665.0m
EBITDA
$-469.7m | $-428.5m
EBIT
$-505.1m | $-478.6m
Net Income
$-532.9m | $-481.4m
Free Cash Flow
$-442.3m
Growth (TTM | estimate)
Revenue
26.8% | 18.7%
EBITDA
8.9% | 19.2%
EBIT
8.0% | 10.7%
Net Income
8.9% | 15.4%
Free Cash Flow
10.2%
Margin (TTM | estimate)
Gross
85.3%
EBITDA
-77.0% | -64.4%
EBIT
-82.8%
Net
-87.3% | -72.4%
Free Cash Flow
-72.5%
More
EPS
$-5.4
FCF per Share
$-4.6
Short interest
9.7%
Employees
1k
Rev per Employee
$430.0k
Show more

Is Ultragenyx Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Ultragenyx Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast:

25x Buy
93%
2x Hold
7%

Analyst Opinions

27 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Ultragenyx Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
610 610
27% 27%
100%
- Direct Costs 90 90
45% 45%
15%
521 521
24% 24%
85%
- Selling and Administrative Expenses 337 337
9% 9%
55%
- Research and Development Expense 688 688
5% 5%
113%
-470 -470
9% 9%
-77%
- Depreciation and Amortization 35 35
7% 7%
6%
EBIT (Operating Income) EBIT -505 -505
8% 8%
-83%
Net Profit -533 -533
9% 9%
-87%

In millions USD.

Don't miss a Thing! We will send you all news about Ultragenyx Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ultragenyx Pharmaceutical, Inc. Stock News

Neutral
The Motley Fool
6 days ago
Ultragenyx (RARE) Q2 Revenue Up 13%
Neutral
Seeking Alpha
7 days ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief Medical Officer & Executive VP Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Joshua Higa - Director of Investor Relations & Corporate C...
Neutral
GlobeNewsWire
7 days ago
Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million
More Ultragenyx Pharmaceutical, Inc. News

Company Profile

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Head office United States
CEO Emil Kakkis
Employees 1,294
Founded 2010
Website www.ultragenyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today